Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: A case report

Recent advances in cancer immunotherapy have been remarkable, with many reports on the clinical effects of immune checkpoint inhibitors. Nivolumab has been covered by the national health insurance in Japan as a third-line agent for advanced and recurrent gastric cancer since September 2017.